Multidisciplinary rehabilitation program in recently hospitalized patients with heart failure and preserved ejection fraction: Rationale and design of a randomized controlled trial

被引:10
|
作者
Koifman, Edward [1 ,2 ,3 ]
Grossman, Ehud [3 ,4 ]
Elis, Avishay [3 ,5 ]
Dicker, Dror [3 ,6 ]
Koifman, Bella [3 ,7 ]
Mosseri, Morris [3 ,8 ]
Kuperstein, Rafael [1 ,2 ,3 ]
Goldenberg, Ilan [1 ,2 ,3 ]
Kamerman, Tamir [1 ]
Levine-Tiefenbrun, Nava [2 ,3 ]
Klempfner, Robert [1 ,2 ,3 ]
机构
[1] Leviev Heart Ctr, Tel Hashomer, Israel
[2] Neufeld Cardiac Res Inst, Tel Hashomer, Israel
[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[4] Chaim Sheba Med Ctr, Internal Med & Hypertens Unit D, IL-52621 Tel Hashomer, Israel
[5] Rabin Med Ctr, Petah Tiqwa, Israel
[6] Hasharon Hosp, Rabin Med Ctr, Internal Med & Obes Clin D, Petah Tiqwa, Israel
[7] Tel Aviv Med Ctr & Sch Med, Cardiol Dept, Tel Aviv, Israel
[8] Meir Med Ctr, Cardiol Div, Kefar Sava, Israel
关键词
EUROPEAN-SOCIETY; HF-ACTION; NATRIURETIC PEPTIDE; OLDER PATIENTS; TASK-FORCE; EXERCISE; ASSOCIATION; MANAGEMENT; DIAGNOSIS; DYSFUNCTION;
D O I
10.1016/j.ahj.2014.08.010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Heart failure with preserved ejection fraction (HFpEF) comprises a large portion of heart failure patients and portends poor prognosis with similar outcome to heart failure with reduced ejection fraction (HFrEF). Thus far, no medical therapy has been shown to improve clinical outcome in this common condition. Trial Design The study is a randomized-controlled, multicenter clinical trial aimed to determine whether early posthospitalization comprehensive cardiac rehabilitation (CR) including exercise training (ET) in recently hospitalized HFpEF patients reduces the composite end point of all-cause mortality and hospitalizations in comparison with usual care (UC). After undergoing baseline evaluation, patients are randomized to either UC or to ambulatory comprehensive CR program. Patients in the CR arm will participate in a 6-month biweekly ET program according to a predefined protocol, in addition to a complementary home exercise prescribed by a specialist in CR. Exercise training will include endurance and low-intensity resistance training. Patients in the UC arm will be followed up at the outpatient clinic, with management according to current heart failure guidelines. Physician follow-up visits will be conducted at 3, 6, and 12 months for assessment of adherence to therapy and ET, functional status, quality of life, and clinical events. Secondary end points will include quality-of-life questionnaire, economic end points, blood pressure, and hemoglobin A(1)C levels. Conclusions Cardiac rehabilitation and ET are relatively inexpensive and accessible and can be beneficial in HFpEF patients. Our trial is designed to evaluate the impact of early posthospitalization comprehensive rehabilitation program on clinical end points of mortality, hospitalization, and quality of life in HFpEF patients.
引用
收藏
页码:830 / +
页数:9
相关论文
共 50 条
  • [1] Personalized pacing for diastolic dysfunction and heart failure with preserved ejection fraction: Design and rationale for the myPACE randomized controlled trial
    Infeld, Margaret
    Wahlberg, Kramer
    Cicero, Jillian
    Meagher, Sean
    Habel, Nicole
    Krishnan, Anand Muthu
    Silverman, Daniel N.
    Lustgarten, Daniel L.
    Meyer, Markus
    HEART RHYTHM O2, 2022, 3 (01): : 109 - 116
  • [2] Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial: A randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction
    Desai, Akshay S.
    Lewis, Eldrin F.
    Li, Rebecca
    Solomon, Scott D.
    Assmann, Susan F.
    Boineau, Robin
    Clausell, Nadine
    Diaz, Rafael
    Fleg, Jerome L.
    Gordeev, Ivan
    McKinlay, Sonja
    O'Meara, Eileen
    Shaburishvili, Tamaz
    Pitt, Bertram
    Pfeffer, Marc A.
    AMERICAN HEART JOURNAL, 2011, 162 (06) : 966 - U27
  • [3] Pirfenidone in Heart Failure with Preserved Ejection Fraction—Rationale and Design of the PIROUETTE Trial
    Gavin A. Lewis
    Erik B. Schelbert
    Josephine H. Naish
    Emma Bedson
    Susanna Dodd
    Helen Eccleson
    Dannii Clayton
    Beatriz Duran Jimenez
    Theresa McDonagh
    Simon G. Williams
    Anne Cooper
    Colin Cunnington
    Fozia Zahir Ahmed
    Rajavarma Viswesvaraiah
    Stuart Russell
    Stefan Neubauer
    Paula R. Williamson
    Christopher A. Miller
    Cardiovascular Drugs and Therapy, 2019, 33 : 461 - 470
  • [4] Dapagliflozin in Patients Recently Hospitalized With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
    Cunningham, Jonathan W.
    Vaduganathan, Muthiah
    Claggett, Brian L.
    Kulac, Ian J.
    Desai, Akshay S.
    Jhund, Pardeep S.
    de Boer, Rudolf A.
    DeMets, David
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Shah, Sanjiv J.
    McGrath, Martina M.
    O'Meara, Eileen
    Wilderang, Ulrica
    Lindholm, Daniel
    Petersson, Magnus
    Langkilde, Anna Maria
    McMurray, John J., V
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2022, 80 (14) : 1302 - 1310
  • [5] Effect of Tai Ji on heart failure with preserved ejection fraction patients:a randomized controlled trial
    王新婷
    ChinaMedicalAbstracts(InternalMedicine), 2022, 39 (04) : 200 - 201
  • [6] Pirfenidone in Heart Failure with Preserved Ejection Fraction-Rationale and Design of the PIROUETTE Trial
    Lewis, Gavin A.
    Schelbert, Erik B.
    Naish, Josephine H.
    Bedson, Emma
    Dodd, Susanna
    Eccleson, Helen
    Clayton, Dannii
    Jimenez, Beatriz Duran
    McDonagh, Theresa
    Williams, Simon G.
    Cooper, Anne
    Cunnington, Colin
    Ahmed, Fozia Zahir
    Viswesvaraiah, Rajavarma
    Russell, Stuart
    Neubauer, Stefan
    Williamson, Paula R.
    Miller, Christopher A.
    CARDIOVASCULAR DRUGS AND THERAPY, 2019, 33 (04) : 461 - 470
  • [7] Interleukin-6 and outcomes in patients recently hospitalized with heart failure and preserved ejection fraction
    Mooney, L.
    Jackson, C. E.
    McConnachie, A.
    Myles, R.
    McMurray, J. J. V.
    Petrie, M. C.
    Jhund, P. S.
    Lang, N. N.
    EUROPEAN HEART JOURNAL, 2021, 42 : 738 - 738
  • [8] Atrial Fibrillation Ablation for Heart Failure With Preserved Ejection Fraction A Randomized Controlled Trial
    Chieng, David
    Sugumar, Hariharan
    Segan, Louise
    Tan, Caleb
    Vizi, Donna
    Nanayakkara, Shane
    Al-Kaisey, Ahmed
    Hawson, Joshua
    Prabhu, Sandeep
    Voskoboinik, Aleksandr
    Finch, Sue
    Morton, Joseph B.
    Lee, Geoffrey
    Mariani, Justin
    La Gerche, Andre
    Taylor, Andrew J.
    Howden, Erin
    Kistler, Peter M.
    Kalman, Jonathan M.
    Kaye, David M.
    Ling, Liang-Han
    JACC-HEART FAILURE, 2023, 11 (06) : 646 - 658
  • [9] Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
    Solomon, Scott D.
    de Boer, Rudolf A.
    DeMets, David
    Hernandez, Adrian F.
    Inzucchi, Silvio E.
    Kosiborod, Mikhail N.
    Lam, Carolyn S. P.
    Martinez, Felipe
    Shah, Sanjiv J.
    Lindholm, Daniel
    Wilderang, Ulrica
    Ohrn, Fredrik
    Claggett, Brian
    Langkilde, Anna Maria
    Petersson, Magnus
    McMurray, John J. V.
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 (07) : 1217 - 1225
  • [10] Heart Rate and Outcomes in Hospitalized Patients With Heart Failure With Preserved Ejection Fraction
    Lam, Phillip H.
    Dooley, Daniel J.
    Deedwania, Prakash
    Singh, Steven N.
    Bhatt, Deepak L.
    Morgan, Charity J.
    Butler, Javed
    Mohammed, Selma F.
    Wu, Wen-Chih
    Panjrath, Gurusher
    Zile, Michael R.
    White, Michel
    Arundel, Cherinne
    Love, Thomas E.
    Blackman, Marc R.
    Allman, Richard M.
    Aronow, Wilbert S.
    Anker, Stefan D.
    Fonarow, Gregg C.
    Ahmed, Ali
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (15) : 1861 - 1871